Terry Chambless
Internal Medicine · Round Rock, UTNPI 1831188572
Payments from drug & device makers
Across 249 payments — averaging $11.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Novo Nordisk$217
- Takeda Pharmaceuticals U.S.A., Inc.$205
- Pfizer$134
- GSK$132
- AstraZeneca$122
- plus $610 from 17 others
What the payments were for
- Food & beverage$2,742100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 155 | $1,323 |
| Novo Nordisk | 13 | $217 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $205 |
| Pfizer | 7 | $134 |
| GSK | 8 | $132 |
| AstraZeneca | 7 | $122 |
| Amarin Pharma, Inc. | 6 | $102 |
| Lilly USA, LLC | 5 | $73 |
| AbbVie(2 entities) | 3 | $55 |
| Novartis | 3 | $54 |
| Phathom Pharmaceuticals, Inc. | 2 | $52 |
| Exact Sciences | 3 | $49 |
| Johnson & Johnson | 3 | $48 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Antares Pharma, Inc. | 2 | $26 |
| Tolmar, Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Corium, LLC | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
| Mannkind Corporation | 1 | $11 |
How this compares
$2,742 in reported general payments places this provider in the 80th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 293 | $201,372 |
| MounjaroTirzepatide | 89 | $106,269 |
| Dupixent SyringeDupilumab | 12 | $55,280 |
| EliquisApixaban | 53 | $51,879 |
| XareltoRivaroxaban | 30 | $46,022 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $35,543 |
| TrintellixVortioxetine Hydrobromide | 19 | $25,878 |
| OzempicSemaglutide | 22 | $18,609 |
| Dexlansoprazole DrDexlansoprazole | 44 | $18,387 |
| Lagevrio (Eua)Molnupiravir | 40 | $17,873 |
| MyrbetriqMirabegron | 17 | $15,797 |
| Ezetimibe | 527 | $12,770 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 42 | $11,627 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 108 | $11,479 |
| Rosuvastatin Calcium | 560 | $9,841 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $73 | $106,26989 claims |
| PfizerEliquis, Premarin | $134 | $61,30672 claims |
| Johnson & JohnsonXarelto | $48 | $46,02230 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $205 | $25,87819 claims |
| Novo NordiskOzempic | $217 | $18,60922 claims |
| GSKArexvy, Shingrix | $132 | $15,13959 claims |
| AstraZenecaSymbicort | $122 | $4,73911 claims |
| AbbVieSynthroid | $55 | $4,28261 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 496 internal medicine providers in Utah.
Other internal medicine in Round Rock
- Ahad SabetSalt Lake City$34.5M
- Barbara RizzardiSandy$27.8M
- Willard DereSalt Lake City$4.7M
- Joseph WoolleySaint George$3.6M
- Justin MansfieldOgden$3.1M
- Michael KillpackSandy$2M
- Cuper Martinez SantibanezWest Valley City$1M
- Joshua OaksBountiful$973K
- Brandon WebbSalt Lake City$544K
- Yong Hui AhnSlc$474K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.